{"id":"W4310779922","doi":"10.1038/s41591-022-02041-5","title":"Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"Roche Diagnostics; Amgen Canada; Pfizer Japan; Novartis Pharma; Esperion Therapeutics; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Teijin Pharma; Otsuka Pharmaceutical; Cytokinetics; Astellas Pharma; Deutsche Forschungsgemeinschaft; Astellas Foundation for Research on Metabolic Disorders; Boehringer Ingelheim Japan; ReCor Medical; Mitsubishi Tanabe Pharma Corporation; Medicines Company; MSD K.K.; AstraZeneca Canada; Siemens Medical Solutions USA; AstraZeneca; Amarin Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Regeneron Pharmaceuticals; Intercept Pharmaceuticals; Bayer HealthCare; Omron Healthcare; Kowa Company; Sanofi; Amgen; Anthera; Vifor Pharma; Actelion Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Ejection fraction; Hazard ratio; Medicine; Heart failure; Internal medicine; Cardiology; Placebo; Clinical endpoint; Confidence interval; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00955193,0.001799758,0.004823858,0.0004621921,0.0002888691,0.001691514,0.001017523,0.001444708,0.002688182],"category_scores_gemma":[0.004454163,0.0006220173,0.01234885,0.0003963813,0.0007799884,0.001048959,0.0008503392,0.002907145,0.0003636944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000515881,"about_ca_system_score_gemma":0.0006633783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004320356,"about_ca_topic_score_gemma":0.001029765,"domain_scores_codex":[0.9956205,0.002844686,0.0003194827,0.0003928426,0.0004293242,0.0003931078],"domain_scores_gemma":[0.9964991,0.001832339,0.0005916094,0.0004662408,0.000184616,0.0004261518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9416348,0.001621994,0.01335446,0.001184966,0.02273338,0.0001622787,0.00005000688,0.001549175,0.004344082,0.0001554828,0.0005463681,0.01266292],"study_design_scores_gemma":[0.4637935,0.2452799,0.1973401,0.0003303907,0.07120501,0.0004962491,0.0001490365,0.009488088,0.007082835,0.001186018,0.003469699,0.0001792735],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98114,0.01142407,0.002674152,0.0003932029,0.000222226,0.0007887926,0.001801349,0.00007113663,0.001485016],"genre_scores_gemma":[0.9938703,0.001259953,0.00101789,0.0004511581,0.0001854495,0.0004142385,0.002045329,0.00001624077,0.0007394537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00955193,"threshold_uncertainty_score":0.05051601,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01971254737780448,"score_gpt":0.2940950505511354,"score_spread":0.2743825031733309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}